Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Thursday

Terns Pharmaceuticals (NASDAQ:TERN) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Terns Pharmaceuticals to post earnings of ($0.30) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:00 PM ET.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.06. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Terns Pharmaceuticals Price Performance

Shares of TERN stock opened at $52.95 on Tuesday. The stock has a market cap of $6.12 billion, a PE ratio of -51.41 and a beta of -0.37. The stock has a 50-day moving average of $50.15 and a 200-day moving average of $38.53. Terns Pharmaceuticals has a one year low of $2.65 and a one year high of $53.19.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at $13,498,068.96. This trade represents a 4.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Emil Kuriakose sold 942 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the transaction, the insider directly owned 105,673 shares in the company, valued at $5,574,250.75. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 30,108 shares of company stock valued at $1,302,370 over the last three months. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Terns Pharmaceuticals during the fourth quarter worth about $25,000. EntryPoint Capital LLC bought a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $206,000. Rafferty Asset Management LLC bought a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $212,000. Mackenzie Financial Corp acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $215,000. Finally, Cibc World Markets Corp acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $229,000. 98.26% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TERN. Mizuho set a $53.00 price target on Terns Pharmaceuticals in a report on Friday, March 27th. Leerink Partners lowered Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Citizens Jmp cut Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a research note on Thursday, March 26th. TD Cowen downgraded shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 target price on the stock. in a report on Thursday, March 26th. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $58.00 price target on shares of Terns Pharmaceuticals in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $55.14.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing oral small?molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.